Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacytarabine plus Idarubicin in Refractory AML
NCT01035502Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- Dec 2009
- Primary completion
- May 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 4
01
Overview
A Phase 2 trial of elacytarabine in acute myeloid leukemia (AML), sponsored by Clavis Pharma. Started Dec 2009; status: completed.
02
Drugs
elacytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01035502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01035502.